Clinical trials
Thrombocytopenia clinical trials
Below are recruiting thrombocytopenia clinical trials, each written for real people, not researchers. We’re tracking 149 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06919341Recruiting
Spanish immune thrombocytopenia registry
This study collects data from people with immune thrombocytopenia (a condition where the immune system destroys platelets, causing low blood counts). It aims to better understand and track the disease over time.
A Coruña, A CoruñaAges 2 months+ - NCT07194850RecruitingPhase 2/Phase 3
Study of Efgartigimod for teens with chronic ITP
This trial tests an IV medicine called efgartigimod for teenagers (ages 12 to under 18) who have had chronic immune thrombocytopenia (ITP) for more than a year. The goal is to see if it can safely help raise platelet counts.
BordeauxAges 12–17 - NCT04800458Recruiting
Testing antibody findings to confirm autoimmune low platelets
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
PessacAges 18 years+ - NCT05980806RecruitingPhase 2
Selinexor for myelofibrosis with low platelets (no prior JAK inhibitors)
This trial tests a drug called selinexor (taken by mouth) for people with myelofibrosis who have low to moderate platelet counts and haven't tried JAK inhibitors yet. It aims to shrink the spleen and improve symptoms.
Duarte, CaliforniaAges 18 years+ - NCT07441720RecruitingPhase 2
Umbilical cord blood for low platelets after cancer therapy
This trial tests whether a one-time infusion of umbilical cord blood cells can safely raise platelet counts in people whose counts dropped after cancer treatment. It is for patients whose low platelets are clearly linked to their cancer therapy and who have no other major health problems.
Hangzhou, ZhejiangAges 12–65 - NCT07586826RecruitingPhase 2
Romiplostim N01 plus ATRA for low platelets after cancer treatment
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
BeijingAges 18 years+ - NCT07586813RecruitingPhase 2
Romiplostim N01 Plus ATRA for Low Platelets After Gut Cancer
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
BeijingAges 18 years+ - NCT06533098RecruitingPhase 3
Nipocalimab vs IVIG for FNAIT in pregnancy
This study tests a new medicine called nipocalimab compared to standard IVIG treatment for pregnant women who are at risk of a serious condition where the mother's antibodies attack the baby's platelets (FNAIT). The goal is to see if nipocalimab can prevent complications like bleeding in the baby.
Birmingham, AlabamaAges 18–45 - NCT07788456RecruitingPhase 4
Sequential combination therapy for newly diagnosed ITP in adults
This study tests a combination of multiple drugs given in sequence to adults with newly diagnosed immune thrombocytopenia (ITP), a condition of low platelets. The goal is to see if this approach improves platelet counts and is safe.
TianjinAges 18–75 - NCT07786077Recruiting
Patient preferences for ITP treatment
This study looks at what patients with ITP prefer in their treatments. It may help doctors understand which treatment options matter most to patients like you.
East Hanover, New JerseyAges 18 years+ - NCT07421167RecruitingPhase 2
Ianalumab with TPO-RA for immune thrombocytopenia
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
Fayetteville, ArkansasAges 18 years+ - NCT06898983RecruitingPhase 2
Romiplostim for low platelets from leukemia treatment
This trial tests a drug called Romiplostim to help raise low platelet counts caused by leukemia treatment. It is for adults with leukemia whose platelets are below 50 and who may benefit from this therapy.
Hefei, AnhuiAges 18–75 - NCT06929299RecruitingPhase 1/Phase 2
Testing STSA-1301 for immune thrombocytopenia (ITP)
This trial tests a new drug called STSA-1301 for people with immune thrombocytopenia (ITP), a condition where the immune system attacks platelets. The study has two parts: one for healthy volunteers to check safety, and one for ITP patients to see if the drug can raise platelet counts and reduce bleeding risk.
Bengbu, AnhuiAges 18–75 - NCT06223607Recruiting
Dual antiplatelet therapy in patients with low platelets
This trial looks at whether taking two blood thinners (aspirin plus clopidogrel or ticagrelor) after a heart stent procedure is safe and effective for people who already have low platelet counts. It may help doctors decide the best treatment for you if you have both low platelets and a stent.
Dallas, TexasAges 18 years+ - NCT06033300Recruiting
Blood cell clumps in heparin-induced low platelets
This study looks at how blood cells clump together in patients who may have heparin-induced thrombocytopenia (HIT), a condition where heparin causes a drop in platelets. It aims to better understand the disease and improve diagnosis.
AmiensAges 18 years+ - NCT05236582RecruitingPhase 2
Herombopag for low platelets from chemotherapy side effects
This Phase 2 trial studies herombopag to raise very low platelet counts caused by chemotherapy and reduce bleeding risk. It may help people whose platelet levels stay too low even after prior standard attempts like rhTPO or IL-11.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT02717039Recruiting
Personalized heparin blood-thinner testing for HIT patients
This study looks at whether genetic and blood test information can help manage heparin-induced thrombocytopenia (HIT), a condition where blood platelets drop after heparin use. If you’ve been evaluated for HIT and received certain heparin medicines, your results may help researchers choose safer, more personalized care.
Tucson, ArizonaAges 18 years+ - NCT07286032RecruitingPhase 3
Study of a pill to raise low platelets after chemo
This study tests an investigational pill (hetrombopag) to see if it can safely raise platelet counts in people with solid tumors whose platelets drop after chemotherapy. If you are receiving platinum- or gemcitabine-based chemo and have low platelets due to chemo, this trial may be an option.
Los Alamitos, CaliforniaAges 18 years+ - NCT07063225RecruitingPhase 2
Romiplostim for low platelets after chemotherapy
This trial tests a drug called romiplostim for patients whose platelet counts stay very low (below 30) for a long time after chemotherapy, even after other treatments have failed. The goal is to see if romiplostim can help raise your platelet count to a safer level.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06456528RecruitingPhase 2/Phase 3
Study of QL0911 for low platelets caused by chemo
This trial tests a new drug called QL0911 to help raise platelet counts in people with cancer whose chemo has caused low platelets. The goal is to see if it can prevent delays in treatment.
HarbinAges 18–75 - NCT07492693RecruitingPhase 2
Preventing low platelets from chemo in GI cancers
This trial tests if hetrombopag can prevent low platelet counts caused by chemotherapy in people with gastrointestinal cancers. It may help reduce the risk of bleeding and the need for platelet transfusions.
ShanghaiAges 18 years+ - NCT04600960RecruitingPhase 2
Eltrombopag to raise low platelets after chemotherapy
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07206823Recruiting
Romiplostim N01 plus rituximab for ITP that didn't respond to oral TPO-RA
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
Suzhou, JiangsuAges 14 years+ - NCT06337474RecruitingEarly Phase 1
CD19 CAR NK cells for hard-to-treat immune thrombocytopenia
This study tests whether a new treatment using specially designed immune cells (CD19 CAR NK cells) can help people with immune thrombocytopenia (ITP) that has not improved with standard treatments. It aims to improve platelet counts and reduce bleeding risk.
Changzhou, JiangsuAges 18–65
Hear when a new Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for thrombocytopenia?
- Yes. Clin2 currently lists 149 recruiting thrombocytopenia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a thrombocytopenia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a thrombocytopenia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.